Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
Adagene Inc. (Nasdaq: ADAG) announced interim results in MSS CRC suggesting that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses, overcoming safety-limited efficacy challenges. The poster presentation at the ASCO 2024 Gastrointestinal Cancers Symposium will feature results of a phase 1b/2 study of ADG126 in combination with pembrolizumab in patients with metastatic microsatellite-stable colorectal cancer.
The interim results of ADG126 in combination with pembrolizumab for treating metastatic microsatellite-stable colorectal cancer (CRC) represent a significant stride in oncology. The ability to administer anti-CTLA-4 therapy at higher doses without compromising safety could potentially improve patient outcomes. CTLA-4 is a critical immune checkpoint that, when inhibited, can enhance the body's immune response against cancer cells. However, previous therapies targeting CTLA-4 have been limited by toxicity at higher doses. The introduction of SAFEbody precision masking technology appears to mitigate these adverse effects, potentially leading to more effective dosing regimens and improved efficacy in CRC treatment.
From a research perspective, the development of ADG126 using SAFEbody technology could set a new precedent in the field of immunotherapy. This innovation addresses the longstanding issue of safety-limited efficacy, which has been a barrier to maximizing the therapeutic potential of CTLA-4 inhibitors. The implications of this study extend beyond CRC, as it might influence the development of other antibody-based therapies. It is crucial to consider the scalability of this technology and its applicability across various types of cancer, which could significantly expand the market for CTLA-4 targeting therapies. Moreover, the combination with pembrolizumab, a PD-1 inhibitor, suggests a synergistic approach that could redefine multimodal treatment strategies.
Adagene's innovation in antibody-based therapies could have notable repercussions in the biotechnology market, particularly within the oncology sector. The successful advancement of ADG126 through clinical trials may attract investor attention and potentially lead to partnerships or licensing deals. Moreover, if the SAFEbody technology proves to be a game-changer for anti-CTLA-4 therapies, it could position Adagene as a key player in the field, with the potential to capture significant market share. However, it's important to monitor the competitive landscape, as other companies may also be pursuing similar advancements in precision masking technologies. The long-term impact on Adagene's stock will likely depend on the continued success of clinical trials, regulatory approvals and eventual market adoption of their therapies.
01/04/2024 - 05:00 AM
- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this proven immunotherapy target -
SAN DIEGO and SUZHOU, China, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.
Details for the poster include:
Title : Results of a phase 1b/2 study of ADG126* (a masked anti-CTLA-4 SAFEbody) in combo with pembrolizumab (Pembro) in patients (Pts) with metastatic microsatellite-stable (MSS) colorectal cancer (CRC)
Date: Saturday, January 20 Time: 6:30 a.m. – 7:55 a.m. Pacific Time Onsite Location: Moscone West Abstract Number: 127 Poster Board: H12 The presentation is embargoed until 5:00 p.m. Eastern Time on January 16 and will subsequently be made available on the Publications page of the company’s website here .
* As of this press release, muzastotug is used as the non-proprietary name for ADG126.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody® , and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
For more information, please visit: https://investor.adagene.com . Follow Adagene on WeChat , LinkedIn and Twitter .
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding certain clinical results of ADG126, the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Investor & Media Contact: ir@adagene.com
What company announced the interim results in MSS CRC?
Adagene Inc. (Nasdaq: ADAG)
What technology was mentioned in the announcement?
SAFEbody precision masking technology
What is the non-proprietary name for ADG126?
Where will the poster presentation take place?
ASCO 2024 Gastrointestinal Cancers Symposium in San Francisco
What type of cancer was the study focused on?
Metastatic microsatellite-stable colorectal cancer
When will the presentation be made available on the company's website?
After 5:00 p.m. Eastern Time on January 16
